RxDoctor Payments Data

Hector Trevino, MD

Family Medicine · Eagle Pass, TXNPI 1346349354

Payments from drug & device makers

$2,013in general payments, 2019–2025

Across 62 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$501
  • Bayer$307
  • Lilly USA, LLC$304
  • Novo Nordisk$253
  • Sanofi-aventis U.S. LLC$153
  • Abbott$109
  • plus $385 from 8 others

What the payments were for

  • Food & beverage$2,013100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,013 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$45,080
Medicare patients
68
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol91$70,487
MounjaroTirzepatide63$68,833
JanuviaSitagliptin Phosphate56$47,487
JardianceEmpagliflozin31$46,464
OzempicSemaglutide42$41,166
LinzessLinaclotide68$40,371
KerendiaFinerenone34$37,996
RexultiBrexpiprazole24$22,414
EliquisApixaban34$17,550
XareltoRivaroxaban52$14,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,742
Tresiba Flextouch U-100Insulin Degludec21$9,618
TradjentaLinagliptin12$8,804
TrintellixVortioxetine Hydrobromide13$6,407
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$5,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$501$73,842105 claims
Lilly USA, LLCMounjaro$304$68,83363 claims
Boehringer IngelheimJardiance, Tradjenta$18$55,26843 claims
Novo NordiskOzempic$253$41,16642 claims
AbbVieLinzess$78$40,37168 claims
BayerKerendia$307$37,99634 claims
Johnson & JohnsonXarelto$56$14,64252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →